Isabella Eckerle to Pandemics
This is a "connection" page, showing publications Isabella Eckerle has written about Pandemics.
Connection Strength
0.079
-
SARS-CoV-2 seroprevalence in COVID-19 hotspots. Lancet. 2020 08 22; 396(10250):514-515.
Score: 0.030
-
Novel SARS-CoV-2 variants: the pandemics within the pandemic. Clin Microbiol Infect. 2021 Aug; 27(8):1109-1117.
Score: 0.008
-
Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series. mSphere. 2020 11 11; 5(6).
Score: 0.008
-
Scientific consensus on the COVID-19 pandemic: we need to act now. Lancet. 2020 10 31; 396(10260):e71-e72.
Score: 0.008
-
Culture-Competent SARS-CoV-2 in Nasopharynx of Symptomatic Neonates, Children, and Adolescents. Emerg Infect Dis. 2020 10; 26(10):2494-2497.
Score: 0.007
-
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020 08 01; 396(10247):313-319.
Score: 0.007
-
Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance. Clin Microbiol Infect. 2021 Nov; 27(11):1695.e7-1695.e12.
Score: 0.002
-
Insights into household transmission of SARS-CoV-2 from a population-based serological survey. Nat Commun. 2021 06 15; 12(1):3643.
Score: 0.002
-
Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT). Emerg Microbes Infect. 2020 Dec; 9(1):2394-2403.
Score: 0.002
-
Diagnostic accuracy of Augurix COVID-19 IgG serology rapid test. Eur J Clin Invest. 2020 Oct; 50(10):e13357.
Score: 0.002
-
Validation of a commercially available SARS-CoV-2 serological immunoassay. Clin Microbiol Infect. 2020 Oct; 26(10):1386-1394.
Score: 0.002
-
Delayed Laboratory Response to COVID-19 Caused by Molecular Diagnostic Contamination. Emerg Infect Dis. 2020 08; 26(8):1944-1946.
Score: 0.002